DAAAK Pharma Int. ASRegistered
Key figures
7 565 196 €−28,4%
Revenue 2025
+13,3%
Average annual growth 2019–2025
Ratios
20250,8%
Profit margin
77,4%
Equity ratio
4,3×
Current ratio
2,4%
Return on equity
2676 €
Average gross salary
Balance sheet structure
Current assetsNon-current assetsLiabilitiesEquity
Quarterly figures
| Quarter | Revenue | Number of employees | Labour taxes |
|---|---|---|---|
| Q2 2026 | 2 781 743 € | 4 | 17 341 € |
| Q1 2026 | 5 943 647 € | 4 | 20 013 € |
| Q4 2025 | 3 001 926 € | 4 | 17 375 € |
| Q3 2025 | 5 243 814 € | 4 | 15 726 € |
| Q2 2025 | 2 372 103 € | 4 | 15 565 € |
| Q1 2025 | 2 756 607 € | 4 | 17 611 € |
Source: Tax Board open data — based on VAT returns, may not exactly match revenue in the annual report. Updated quarterly.
Summary of financial statements2019–2025
| 2019 † | 2020 † | 2021 † | 2022 † | 2023 † | 2024 † | 2025 | |
|---|---|---|---|---|---|---|---|
| Balance sheet — assets | |||||||
| Total current assets | 1 383 842 | 1 328 401 | 1 883 699 | 2 750 602 | 8 656 462 | 3 097 826 | 3 220 165 |
| Total non-current assets | 321 021 | 273 589 | 93 725 | 73 369 | 64 264 | 144 704 | 75 529 |
| Total assets | 1 704 863 | 1 601 990 | 1 977 424 | 2 823 971 | 8 720 726 | 3 242 530 | 3 295 694 |
| Balance sheet — liabilities and equity | |||||||
| Current liabilities | 790 080 | 786 435 | 1 432 081 | 2 128 085 | 5 935 487 | 753 548 | 746 320 |
| Non-current liabilities | 32 088 | 21 392 | 9751 | 0 | 0 | — | — |
| Total liabilities | 822 168 | 807 827 | 1 441 832 | 2 128 085 | 5 935 487 | 753 548 | 746 320 |
| Share capital | 25 000 | 25 000 | 25 000 | 25 000 | 25 000 | 25 000 | 25 000 |
| Retained earnings of previous periods | 773 705 | 632 181 | 699 163 | 250 582 | 260 886 | 2 750 239 | 2 453 982 |
| Profit for the year | 73 990 | 126 982 | −198 571 | 410 304 | 2 489 353 | −296 257 | 60 392 |
| Reserves and other equity | 10 000 | 10 000 | 10 000 | 10 000 | 10 000 | 10 000 | 10 000 |
| Total equity | 882 695 | 794 163 | 535 592 | 695 886 | 2 785 239 | 2 488 982 | 2 549 374 |
| Income statement | |||||||
| Sales revenue | 3 569 799 | 4 249 009 | 4 857 922 | 4 088 283 | 17 441 725 | 10 570 895 | 7 565 196 |
| Operating profit | 60 635 | 213 194 | −172 087 | 455 204 | 2 540 115 | −229 980 | 95 712 |
| EBITDA | — | — | — | — | 2 550 990 | — | — |
| Profit before income tax | 78 990 | 180 279 | −188 804 | 446 713 | 2 500 748 | −218 394 | 60 392 |
| Profit for the reporting year | 73 990 | 126 982 | −198 571 | 410 304 | 2 489 353 | −296 257 | 60 392 |
| Labour costs | 157 925 | 187 901 | 197 704 | 185 411 | 244 230 | 305 500 | 286 781 |
| Depreciation of non-current assets | — | — | — | — | 10 875 | — | — |
| Other indicators | |||||||
| Employees | 11 | 13 | 10 | 10 | 11 | 15 | 11 |
| Calculated dividend | — | — | — | — | — | — | — |
A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report. † Figures for the marked years come from a report filed as PDF and may be incomplete.
Connections graph
Click a node to see its other connections.
CompanyPersonShareholderOther roleAdditional link
Related companies
Same activity — Ravimite ja muude apteegikaupade hulgimüük